Ginisortamab (UCB6114) is a new monoclonal antibody being developed to treat advanced solid tumors, especially gastrointestinal cancers. Instead of attacking cancer cells directly, it targets the tumor’s surrounding support cells to weaken the tumor’s defenses.
The therapy focuses on a protein called gremlin-1, produced by cancer-associated fibroblasts around the tumor. Gremlin-1 blocks natural tumor-suppressing proteins called BMPs, keeping cancer cells in a stem-like state that allows rapid growth and treatment resistance. Ginisortamab binds to gremlin-1, restoring the body’s natural anti-tumor signals and making the cancer more sensitive to chemotherapy.
Early clinical trials showed that ginisortamab is safe both alone and with standard chemotherapies. Some patients experienced tumor shrinkage, and many achieved disease control, especially in metastatic colorectal and gastroesophageal cancers. Based on these promising results, the drug is now in Phase 2 trials for metastatic pancreatic cancer, being tested both with chemotherapy and as a maintenance therapy with a MEK inhibitor.